Compliance Rate

Compliance Rate 50.0%
Compliant submissions 1
Incompliant submissions 1
Total trials 2

My Organizations' Clinical Trials

Showing 2625 of 3499 entries
View as:

Bicalutamide and RO4929097 in Treating Patients With Previously Treated Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01200810 Org: User:
Start: 08/31/10 End: 11/30/12 Due: 11/30/13

Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma

Phase: N/A Priority: Normal
NCT ID: NCT01154452 Org: User:
Start: 06/30/10 End: 02/28/15 Due: 02/28/16

A Pilot Study of F-18 Paclitaxel (FPAC) PET for Evaluating Drug Delivery of Solid Tumors in Breast, Lung, Renal, and Adrenal Cancers

Phase: N/A Priority: Normal
NCT ID: NCT01086696 Org: User:
Start: 03/09/10 End: 05/11/16 Due: 05/11/17

Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Treatment of Metastatic or Recurrent Breast or Castrate-Resistant Prostate Cancer With BRCA Mutations

Phase: N/A Priority: Normal
NCT ID: NCT05807126 Org: User:
Start: 03/05/24 End: 12/06/26 Due: 12/06/27

Internet Support Group for Parents of a Child With Neurofibromatosis Type 1

Phase: N/A Priority: Normal
NCT ID: NCT02153931 Org: User:
Start: 05/31/14 End: 01/29/19 Due: 01/29/20

Biomarkers in Predicting Treatment Response in Samples From Patients With Early-Stage Non-Small Cell Lung Cancer Previously Treated With Adjuvant Chemotherapy

Phase: N/A Priority: Normal
NCT ID: NCT01595074 Org: User:
Start: 05/31/12 End: - Due: -

O(6)-Benzylguanine and Temozolomide in Treating Patients With Glioblastoma Multiforme That Did Not Respond to Previous Temozolomide and Radiation Therapy

Phase: N/A Priority: Normal
NCT ID: NCT00436436 Org: User:
Start: 11/13/06 End: 04/14/10 Due: 04/14/11

Calibration of Urine pH Strips for NCI Case-Control Studies on Bladder Cancer and Comparison of DNA Yields From Buccal Cells Collected Through Two Different Methods

Phase: N/A Priority: Normal
NCT ID: NCT00339443 Org: User:
Start: 11/06/01 End: 05/19/10 Due: 05/19/11

Extended Follow Up of Young Women in Costa Rica Who Received Vaccine for Human Papillomavirus Types 16 and 18 and Unvaccinated Controls

Phase: N/A Priority: Normal
NCT ID: NCT00867464 Org: User:
Start: 03/30/09 End: 12/31/25 Due: 12/31/26

Improving the Immune System With Human IL-7 Vaccine in Older Subjects Who Have Had Chemotherapy

Phase: N/A Priority: Normal
NCT ID: NCT01339000 Org: User:
Start: 04/30/11 End: 04/30/16 Due: 04/30/17

PU-H71 in Patients With Solid Tumors and Low-Grade Non-Hodgkin's Lymphoma That Have Not Responded to Standard Treatment

Phase: N/A Priority: Normal
NCT ID: NCT01581541 Org: User:
Start: 04/26/11 End: 09/03/14 Due: 09/03/15

Natural History Study of Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Myeloma (SMM)

Phase: N/A Priority: Normal
NCT ID: NCT01109407 Org: User:
Start: 04/22/10 End: 02/25/21 Due: 02/25/22

A Pilot Trial of Oral Topotecan for the Treatment of Refractory Advanced Solid Neoplasms Expressing HIF-1a

Phase: N/A Priority: Normal
NCT ID: NCT00117013 Org: User:
Start: 06/28/05 End: 10/25/10 Due: 10/25/11

Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Advanced, Metastatic, or Recurrent Non-Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00021060 Org: User:
Start: 08/31/02 End: - Due: -

Testing the Addition of a Radiation Sensitizing Drug, IPdR, to the Usual Chemotherapy Treatment (Capecitabine) During Radiation Therapy for Rectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04406857 Org: User:
Start: 03/17/21 End: 01/18/23 Due: 01/18/24

Clinical, Genetic, Behavioral, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Breast/Ovarian Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00040222 Org: User:
Start: 07/01/02 End: - Due: -

Veliparib With or Without Carboplatin in Treating Patients With Stage III or IV Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01149083 Org: User:
Start: 06/30/10 End: 09/30/24 Due: 09/30/25

Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study

Phase: N/A Priority: Normal
NCT ID: NCT04500548 Org: User:
Start: 01/28/21 End: 06/21/22 Due: 06/21/23

Vorinostat in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver Dysfunction

Phase: N/A Priority: Normal
NCT ID: NCT00499811 Org: User:
Start: 06/30/07 End: - Due: -

Natural History of Patients With Brain and Spinal Cord Tumors

Phase: N/A Priority: Normal
NCT ID: NCT00009035 Org: User:
Start: 01/22/01 End: 09/11/18 Due: 09/11/19

Studying Normal Breast Tissue and Cancer Risk

Phase: N/A Priority: Normal
NCT ID: NCT00341692 Org: User:
Start: 04/07/03 End: 04/28/20 Due: 04/28/21

Cyclophosphamide, Alvocidib, and Rituximab in Treating Patients With High Risk B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT01076556 Org: User:
Start: 04/30/10 End: - Due: -

Testing Nivolumab as a Potential Targeted Treatment in Cancers With Mismatch Repair Deficiency (MATCH-Subprotocol Z1D)

Phase: N/A Priority: Normal
NCT ID: NCT04439214 Org: User:
Start: 05/31/16 End: 05/17/20 Due: 05/17/21

Effect of Lifestyle Factors and Hormone Function on Breast Density in Healthy Hispanic Women Who Are Undergoing Mammography for Breast Cancer Screening

Phase: N/A Priority: Normal
NCT ID: NCT00131950 Org: User:
Start: 08/31/03 End: 11/30/05 Due: 11/30/06

Sunitinib in Sarcomas of the Central Nervous System

Phase: N/A Priority: Normal
NCT ID: NCT03641326 Org: User:
Start: 02/21/19 End: 04/02/21 Due: 04/02/22